Sensitivity of modeled cell trajectories to parameter perturbations. حسب Renad Al-Ghazawi (22411258)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... حسب Xinhang Gu (22686224)

"…Compared with the TKI-alone group, the TKI+TRT group presented significantly better PFS (28.6 vs. 19.8 months, hazard ratio [HR]=0.48, P = 0.00024) and OS (42.2 vs. 35.1 months, HR = 0.54, P = 0.039). …"

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …"

Stata file for the experimental hut data. حسب Jackline L. Martin (12265386)

"…A small, non-significant effect of pyriproxyfen on <i>Anopheles</i> fertility was observed for Royal Guard up to 12 months (75% vs 98%, OR: 1.1, 95% CI: 0.0–24.9, p-value = 0.951). …"

EHT treatments evaluated. حسب Jackline L. Martin (12265386)

"…A small, non-significant effect of pyriproxyfen on <i>Anopheles</i> fertility was observed for Royal Guard up to 12 months (75% vs 98%, OR: 1.1, 95% CI: 0.0–24.9, p-value = 0.951). …"

DtpT transports structurally diverse di-/tripeptides. حسب Imran Khan (109715)

Image 2_Impaired K48-polyubiquitination downmodulates mouse norovirus propagation.tiff حسب Emmrich Wakeford (21249104)

"…Consequently, the number of viral genome copies or viral titers were also significantly decreased in the YFP-Ubiquitin_K48R cells compared to the YFP-Ubiquitin_WT cells. …"